Compare · MRNA vs RGEN
MRNA vs RGEN
Side-by-side comparison of Moderna Inc. (MRNA) and Repligen Corporation (RGEN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRNA and RGEN operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $18.82B, about 2.7x RGEN ($6.90B).
- Over the past year, MRNA is up 68.5% and RGEN is down 7.1% - MRNA leads by 75.6 points.
- MRNA has been more active in the news (12 items in the past 4 weeks vs 11 for RGEN).
- Both have 25 recent analyst ratings on file.
- Company
- Moderna Inc.
- Repligen Corporation
- Price
- $47.41-8.12%
- $122.37-3.33%
- Market cap
- $18.82B
- $6.90B
- 1M return
- -2.76%
- -2.73%
- 1Y return
- +68.54%
- -7.10%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 1986
- News (4w)
- 12
- 11
- Recent ratings
- 25
- 25
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Repligen Corporation
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company offers filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE and FlowVPE brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands; and Sartorius Stedim Biotech to create novel perfusion-enabled bioreactors. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Latest MRNA
- Chief Financial Officer Mock James M converted options into 2,475 shares and covered exercise/tax liability with 1,197 shares, increasing direct ownership by 2% to 59,594 units (SEC Form 4) to satisfy tax liability
- Chief Legal Officer Klinger Shannon Thyme converted options into 2,165 shares and covered exercise/tax liability with 1,047 shares, increasing direct ownership by 2% to 67,468 units (SEC Form 4) (tax withholding)
- President Hoge Stephen converted options into 9,282 shares and covered exercise/tax liability with 4,488 shares, increasing direct ownership by 0.32% to 1,483,848 units (SEC Form 4) to satisfy tax liability
- Moderna to Present at Upcoming Conference in June 2026
- Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting
- Moderna and CEPI Expand Strategic Collaboration to Advance Potential Vaccine Against Bundibugyo Ebolavirus
- Chief Financial Officer Mock James M converted options into 1,101 shares and covered exercise/tax liability with 533 shares, increasing direct ownership by 0.98% to 58,316 units (SEC Form 4) to satisfy tax liability
- Chief Legal Officer Klinger Shannon Thyme converted options into 1,101 shares and covered exercise/tax liability with 533 shares, increasing direct ownership by 0.86% to 66,350 units (SEC Form 4) (for tax liability)
- President Hoge Stephen converted options into 2,047 shares and covered exercise/tax liability with 990 shares, increasing direct ownership by 0.07% to 1,479,054 units (SEC Form 4) (tax liability)
- Director Afeyan Noubar exercised 9,263 shares at a strike of $19.15 and sold $433,879 worth of shares (9,263 units at $46.84) (SEC Form 4)
Latest RGEN
- Wolfe Research resumed coverage on Repligen with a new price target
- Repligen Corporation to Present at William Blair 46th Annual Growth Stock Conference
- Repligen Announces Publication of the Company's 2025 Corporate Sustainability Report
- Director Pax Margaret was granted 995 shares, increasing direct ownership by 49% to 3,011 units (SEC Form 4)
- Director Eglinton Manner Carrie was granted 995 shares, increasing direct ownership by 22% to 5,461 units (SEC Form 4)
- Director Mhatre Rohin was granted 995 shares, increasing direct ownership by 25% to 5,014 units (SEC Form 4)
- Director Madaus Martin D was granted 995 shares, increasing direct ownership by 18% to 6,581 units (SEC Form 4)
- Director Konstantinov Konstantin was granted 995 shares, increasing direct ownership by 34% to 3,889 units (SEC Form 4)
- Director Dawes Karen A was granted 995 shares, increasing direct ownership by 1% to 92,816 units (SEC Form 4)
- Director Barthelemy Nicolas was granted 995 shares, increasing direct ownership by 22% to 5,436 units (SEC Form 4)